Huvepharma Inc. announced an agreement to acquire Viridus Animal Health (a subsidiary of Novus International Inc.) which manufactures and sells Advent Coccidiosis Vaccine. Huvepharma expects the transaction to close in early April 2014.

Advent is a market leading coccidiosis vaccine that was introduced by Novus International to the U.S. poultry market in 2003. The Advent vaccine's proven performance for controlling coccidiosis in broiler chickens can be attributed to its differentiated and patented VIACYST assay. This unique feature accurately quantifies the number of live, sporulated coccidial oocysts in Advent. Only viable, sporulated oocysts are capable of imparting immunity and generating resistance to a coccidiosis challenge. Advent is a versatile anticoccidial product that can be used in all broiler production systems while delivering excellent control of this important and economically impactful disease.


"We are extremely excited about Viridus Animal Health and Advent joining the Huvepharma family as the addition complements our solutions approach strategy and builds on our leadership position in coccidiosis control. Novus successfully developed and launched a uniquely innovative product with Advent and it's our desire to expand on their success and innovation. Also, with Huvepharma's international presence, we feel there is a great opportunity to introduce Advent to applicable new markets worldwide. Huvepharma and Novus are committed to providing a seamless transition for all customers over the next several weeks." - Glen Wilkinson, president of Huvepharma Inc.

"I am pleased to see our Advent business join the Huvepharma family. I am confident that Huvepharma's animal health capabilities and portfolio synergies will lead to accelerated growth for Advent for years to come, " said Francois Fraudeau, COO of Novus International Inc.